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The transferrin receptor (TfR) is a promising target in cancer 
therapy owing to its overexpression in most solid tumors and 
on the blood brain barrier. Nanostructures chemically 
derivatized with transferrin are employed in TfR targeting but 
often lose their functionality upon injection in the 
bloodstream. As an alternative strategy, we rationally 
designed a peptide coating able to bind transferrin on suitable 
pockets not involved in binding to TfR or iron, by using an 
iterative multiscale-modeling approach coupled with 
Quantitative Structure-Activity and Relationship (QSAR) 
analysis and evolutionary algorithms. We tested that selected 
sequences have low aspecific protein adsorption and high 
binding energy towards transferrin, and one of them is 
efficiently internalized in cells with a transferrin-dependent 
pathway. Furthermore, it promotes transferrin-mediated 
endocytosis of gold nanoparticles by modifying their protein 
corona and promoting oriented adsorption of transferrin. This 
strategy leads to highly effective nanostructures, potentially 
useful in diagnostic and therapeutic applications, which 
exploit -and do not suffer- the protein solvation for achieving 
a better targeting.  
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The use of targeted delivery systems able to convey a 
molecular payload in diseased tissues is one of the most 
ambitious goals of current nanomedicine research. 
Nanostructured materials play a pivotal role in this field, 
owing to their straightforward surface derivatization, high 
loading capability, and intriguing potential as contrast agents 
in vivo.1 Selectivity towards specific pathologic tissues can be 
conferred by covalent decoration with proteins2, antibodies,3 
aptamers,4,5 and small ligands,6 which recognize receptors 
differentially expressed between pathologic and healthy 
tissues. This strategy, however, often leads to unsatisfying 
results in vivo, owing to the high free energy of nanoparticles 
surface that promote the formation of a protein shell (the 
“protein corona”)7 which solvates the nanostructure upon 
injection in the bloodstream. The structure and the 
composition of the protein corona depends on the physico-
chemical properties of nanoparticles like size, shape, colloidal 
stability, surface charge and its distribution.8 Because of the 
presence of this biological milieu, nanoparticles may lose 
specificity and targeting capabilities of the functional groups 
on their surface, thus reducing or modifying cellular uptake.9 
An elegant alternative is represented by the modulation of 
the protein corona composition, which leads to 
nanostructures that acquire selectivity directly in the 
bloodstream.10 This strategy requires ligands that bind 
specific serum proteins without altering their biological 
function. Indeed, the effect of this “protein corona” 
modulation could confer intriguing homing properties to 
nanostructured systems, which are particularly susceptible of 
serum protein solvation and could better exploit the presence 
of an actively targeting protein shell. How to select these 
sequences, however, remains challenging. Empirical 
approaches such as phage display, yeast-two-hybrid, and 
Systematic Evolution of Ligands by Exponential Enrichment 
(SELEX) would provide unsatisfactory results, due to the 
unpredictable binding site on the target protein, which could 
lose its biological function.11,12 Additionally, these techniques 
require relatively large amounts of target protein, which can 
be difficult to produce. Conversely, computationally driven 
design can provide ligand sequences able to recognize 
selectively a specific non-binding domain of the target 
protein, leaving unaltered its biological function. Transferrin 
receptor (TfR) is a trans-membrane protein formed by two 
subunits that mediate iron transport and cell growth 
regulation. Each subunit can bind one transferrin (Tf) 
molecule loaded with two iron ions that are internalized 
exploiting clathrin-mediated endocytosis.13 TfR is 
ubiquitously expressed at low levels in human tissues,14 and 
highly overexpressed in proliferating cells. It is commonly 
accepted that TfR expression is correlated with tumor 
progression,15 and its expression on the surface of tumor cells 
makes TfR a therapeutic target for solid tumors treatment.16 
Furthermore, it plays a principal role in promoting 
translocation of iron across the blood brain barrier, and is a 
promising “Trojan horse” to perform delivery to the brain of 
otherwise non-permeant structures. Its natural ligand 
transferrin (Tf) has been exploited for delivery of small 
drugs,17,18 toxins,19 enzymes,20 and nucleic acids.21 Tf is 
present at high concentrations in blood, and represents an 
ideal target for the validation of our rational design strategy. 
Here, we show the results on the rational development and 
in vitro evaluation of transferrin-binding peptides. 
 
RESULTS AND DISCUSSION 
 
Rational design of transferrin-binding peptides 
First, we developed a generic method for the virtual screening 
of peptide docking using Martini Coarse Grained (CG)22 force 
field for protein. The method (Figure 1A) consists of an 
iterative procedure that combines the use of bash script, 
python, java, and GROMACS tools to automatically dig in the 
sequence the space for the optimal docking of peptide. 
Starting from the crystal structure of diferric transferrin 
(3V83A),23 we identified using the Fpocket webserver24 five 
potential binding sites (Figure 1B). Selection of the most 
appropriate binding pocket was performed with two aims in 
mind: the ideal pocket should be large enough to 
accommodate a peptide, and should not be near the binding 
site for the transferrin receptor or for iron. The first 
requirement allows selecting sequences with sufficiently high 
Figure 1. Virtual screening method. A) Diagram showing the steps for the virtual screening. B) Pockets identified on the human 
transferrin. Transferrin is represented with the blue ribbon diagram, part of the ectodomain of the transferrin receptor dimer23 is 
rendered by its accessible surface. Pocket 3 (orange) is the one chosen to dock the peptide on the bases of the available volume and 
on the distance from the iron binding site. 
 
affinity, while the second should minimize interference of 
potentially bulky payloads on binding processes to TfR and 
iron ions. These requirements led to the choice of Pocket 3 
(Figure 1B) as the most appropriate site, and preliminary 
measurements suggested that this site could accommodate 
up to six amino acids. This is a sufficiently long sequence to 
provide good binding affinity and selectivity, yet short enough 
to allow exploring a reasonable number of combinations. Our 
strategy involves several computational steps in which a 
mathematical model describing the physico-chemical 
requirements for binding is inferred from molecular dynamics 
simulation data. In this iterative procedure, a set of peptide 
sequences is generated at each step and the linear 3D 
structure of each peptide is built and placed within the 
binding pocket. The peptide is docked using coarse grained 
molecular dynamics simulations (Figure 2A). The free binding 
energy of the docked poses is estimated using the molecular 
mechanics Poisson-Boltzmann surface area (MM-PBSA) 
method.25 To design new candidates for the next iterative 
step, each peptide sequence is encoded into a number of 
descriptors related to its physico-chemical features and 
associated to the theoretical binding energy (Table S1). A 
regression model is then inferred by combining the encoded 
information from all the previous steps, thus obtaining at 
each iteration a mathematical model that better perceives 
bioactive sequences. The regression model is combined to 
multi-objective evolutional algorithms (MOEA) to design 
candidate sequences for the next iteration with optimal 
properties. In this phase, sequence optimization is carried out 
with two different objectives: having the lowest binding free 
energy, and the lowest number of charged/hydrophobic 
sequences (Figure 2B). The last requirement accounts for the 
need to limit aspecific adsorption to serum proteins, which is 
particularly relevant for positively charged or highly 
hydrophobic structures. The algorithm resulted in a 
distributed population of binding peptides, with some 
candidate sequences that better fit the requirement of high 
binding and low net charge/hydrophobicity. In fact, the MOEA 
does not identify the best solution, but a set of sub optimal 
solutions at the given problem. The entire procedure 
(sequence design, docking, scoring) were repeated iteratively 
(Figure 2B). The top three peptides (Tf1, Tf2, Tf3) designed by 
the MOEA at the last iteration were selected for experimental 
evaluation, along with a scrambled version of Tf2 acting as 
control sequence. 
 
Figure 2: A) Three dimensional docked poses. Representative 
docked poses, obtained from a cluster analysis of equilibrium 
all-atoms trajectories, for Tf1, Tf2, Tf2-scrambled, and Tf3 
(see Method Section). Hydrogen bonds (green dashed lines) 
and salt bridges (red dashed lines) formed between the 
peptide and the amino acids in the Tf1 pocket are shown. 
Atoms are colored according to their root mean squared 
displacement, blue: rigid regions, red: flexible regions. Black 
dashed lines highlight solvent exposed atoms. B) Results of 
the virtual screening, showing the distribution of the 
theoretical binding energy versus peptide hydrophobicity 
measured with the combined consensus hydrophobicity scale 
(CCS).26,27 Color scale represents peptides net charge at pH 7 
(red: negative, magenta: positive). 
 
Quartz Crystal Microbalance with Dissipation 
Monitoring (QCM-D) measurements 
We synthesized the selected peptides (Tf1, Tf2, Tf3, and 
Tf2scr, Table 1) by standard solid phase synthesis. All the 
sequences were provided with a spacer (GGG) with an N-
terminal cysteine, to allow conjugation with fluorescent 
reporters or binding to gold-coated surfaces without 
hampering binding with Tf. We then evaluated Tf binding 
affinity of Tf1, Tf2, and Tf3 by measures with a quartz crystal 
microbalance (QCM-D). Peptides were immobilized on a gold 
sensor and increasing concentrations of human Tf were 
injected sequentially (Fig S1). The resonance frequency shift 
was used to calculate the binding constant (Ka) and its 
reciprocal (Kd) using Langmuir equation.  
Table 1: Dissociation constants obtained from quartz-crystal 
microbalance measurements using transferrin and BSA at 25 
°C in PBS. 
 
Name Sequence KdTf μM KdBSA μM Selectivity 
(KdBSA/KdTf) 
Tf1 CGGGPFWWWP 1.21±0.06 1.98±0.33 1.63 
Tf2 CGGGHKYLRW 0.90±0.25 2.61±0.38 2.9 
Tf3 CGGGKRIFMV 6.64±0.08 1.70±0.46 0.25 
Tf2-scr CGGGKWHYLR 9.05±0.3 8.20±0.39 0.90 
 
To assess the amount of aspecific adsorption to serum 
proteins, we also evaluated Kd towards BSA, in view of its high 
concentration in serum (up to 40 mg/mL) and known 
interaction with charged and hydrophobic peptides and 
biomolecules. We observed that both Tf1 and Tf2 bind to Tf 
with Kd in the low micromolar range, while Tf2-scr is markedly 
less efficient (Table 1). The higher efficiency of Tf2 compared 
with Tf2-scr evidences the pivotal role of amino acid 
sequence, and therefore of specific interactions, in 
determining binding to the protein target. The more 
hydrophobic Tf3 has a relatively low binding affinity (Kd= 
6.64±0.08 μM), not far from the one of the control sequence 
Tf2-scr. Note that the relatively high Kd observed for Tf2 is in 
line with what observed for other protein-binding short 
peptide aptamers.28,29 Additionally, it is actually sufficient to 
allow efficient interaction with Tf in biological media, since 
serum concentration of this protein is approximately 35 μM30. 
Not surprisingly, Tf2-scr shows nearly identical affinity 
towards BSA and Tf, while aspecific adsorption in the case of 
Tf3 was even greater than specific interaction with Tf. 
Conversely, both Tf1 and Tf2 have sensibly higher selectivity 
towards Tf (1.63 and 2.9 for Tf1 and Tf2, respectively, Table 
1). This preliminary screening evidenced that Tf2 has both the 
highest Kd and best selectivity, so we selected only this 
sequence for further investigations. 
 
Internalization assay in living cells 
We sought to evaluate whether the observed binding 
properties of Tf2 could translate in efficient transferrin-
mediated internalization. To this end, we labeled Tf2 with the 
commercial far red dye Atto-633 by standard thiol-maleimide 
coupling. Peptide was incubated with cultured 
adenocarcinoma pancreatic cells (Mia PaCa-2), a cell line 
expressing high levels of TfR,31 in the presence of 
physiological (35 µM) levels of Tf. Internalization was 
assessed by confocal fluorescence microscopy (Figure 2) and 
compared with signal arising from fluorescent endocytosis 
markers (fluorescent transferrin for clathrin, dextran-70kDa-
FITC for macropinocytosis, and caveolin-GFP for caveolae), to 
assess the internalization pathway. Indeed, specific 
transferrin mediated internalization should only occur by 
clathrin pathway, a typical route for TfR-mediated 
transport.4,5 Other common internalization pathways, such as 
caveolae or micropinocytosis, would indicate occurrence of 
aspecific processes. As a negative control, we also evaluated 
the internalization of Tf2 in the absence of Tf and Tf2-scr in 
presence of physiological levels of Tf (Fig. S2). In both cases 
(i.e. either using Tf2 or Tf2-scr respectively in the absence or 
presence Tf) we observed minimal internalization, likely due 
to a minor contribution from aspecific interaction of peptides 
with serum proteins, or (less likely) by a low aspecific 
internalization. Conversely, when Tf2 was incubated with 
physiological levels of Tf, we observed extensive 
internalization upon short incubation times. Endocytosis 
occurs essentially by clathrin mediated pathway (Pearson’s 
Coefficient of 0.69±0.09, Fig. 3a-b). In keeping with the 
reported internalization pathway of transferrin, we also 
observed extensive colocalization at lysosomal level, with a 
Pearson’s Coefficient of 0.59±0.08 (Fig. 3c). Conversely, 
colocalization with either macropinocytosis or caveolin 
markers (Fig 3d-e) was negligible (Pearson’s Coefficient of 
0.09±0.07 and 0.06±0.02 respectively); in these cases, 
internalization was smaller because of the lower levels of 
total Tf in the medium. Finally, we confirmed the absence of 
aspecific, passive internalization mechanisms by performing 
competitive inhibition experiments (Fig S3). Internalization of 
Tf2-Atto633 (1µM) was completely inhibited when the 
peptide was incubated either with a saturating excess of 
unlabeled Tf2 (1 mM) or with Tf (600 uM), confirming the 
absence of passive internalization mechanisms. Overall, these 
experiments confirmed that internalization of Tf2 occurs by 
transferrin-mediated endocytosis, with minimal aspecific 
uptake.  
 
Figure 3: Internalization assay in adenocarcinoma pancreatic 
cells (Mia PaCa-2). Each peptide labelled with Atto633 (red 
channel) was incubated in cultured cells at concentration of 1 
μM for 30 minutes at 37°C and 5% CO2 and then 
internalization was monitored by confocal fluorescence 
microscopy. (a,b) Evaluation of clathrin-mediated 
endocytosis for Tf2-Atto633 incubated with hTransferrin-
Alexa488, at concentration of 5 μM (green channel). (c) 
Confirmation of lysosomal internalization with Lysotracker 
Green at concentration of 70 nM (green channel). (d) 
Evaluation of macropinocytosis with Dextran(70kDa)-FITC, 1 
mg/ml (green channel). (e) Analysis of caveolin-mediated 
endocytosis whit Mia PaCa-2 cells transfected with Caveolin-
GFP fusion protein (green channel). Scale bars: 10 μm. 
Internalization of gold nanoparticles conjugated to Tf2 
Finally, we turned our attention to the ability of Tf2 to 
vehiculate nanostructured payloads in cells, to evaluate the 
effect of the protein corona modulation on the internalization 
of metal nanoparticles. To this end, we employed gold 
nanoparticles (30 nm), whose concentration in biological 
samples can be easily and precisely quantified by ICP-MS 
analysis. On the basis of our longstanding experience in the 
synthesis and functionalization of gold nanoparticles,32,33 we 
derivatized the nanoparticles (Au-NPs) with two peptides: an 
already reported stabilizer (peptide N)34, which prevents 
nanoparticle aggregation in solution, and a cognate of Tf2, 
PepN-Tf2 (CLPFFDPPPPHKYLRW). This peptide was designed 
using the base sequence of peptide N (in bold), and adding 
the already used proline spacer and Tf2. This design allows for 
highly efficient formation of a self-assembled monolayer 
(SAM), and leaves the targeting sequence projected outward 
-owing to the polyproline spacer- with minimal steric clash. 
Tf2 peptide was co-formulated in different proportions (0, 1 
and 10% w/w) with peptide N (CLPFFD), and these mixtures 
were used to coat the surface of 30 nm gold nanoparticles, 
leading to AuNP-0, AuNP-1, and AuNP-10, respectively. 
Nanoparticles bearing more than 10% of PepN-Tf2 are not 
stable in water solution, presumably due to the lowered 
surface charge; indeed, an immediate disappearance of the 
plasmon resonance at 530 nm and appearance of a purple 
color was observed upon addition of peptides, indicating the 
presence of large gold aggregates.34 To evaluate aspecific 
protein adsorption and mimic bloodstream conditions, 
coated nanostructures were firstly incubated in pure human 
plasma in physiological conditions (1 h at 37°C) to promote 
formation of a protein corona. Immediately before incubation 
with cells (Mia PaCa-2), the nanoparticle suspension was 
diluted with DMEM to a final plasma concentration of 10%. 
After short incubation (30 minutes) and accurate washing 
with I2/KI solution to remove externally adherent 
nanoparticles,35 we quantified intracellular gold content by 
ICP-MS (Figure 4). Interestingly, we observed that 
internalization of gold nanoparticles is strongly dependent on 
the amount of PepN-Tf2 (and hence of Tf2 sequences) on the 
surface. Indeed, internalization of AuNP-10 was 44-fold 
greater compared with what observed for AuNP-0. The 
limited, yet not negligible, internalization of untargeted 
AuNP-0 can be rationalized in view of the known ability of 
small nanoparticles to internalize in living cells even in the 
absence of targeting sequences, and could be minimized by 
suitable engineering of the SAM coating on the nanoparticle. 
These findings indicate that the presence of Tf2 significantly 
promotes receptor-mediated internalization of 
nanostructured payloads. Not surprisingly, internalization 
correlates with the percentage of targeting peptide Tf2 on the 
nanoparticle, which in turns is related to the amount of 
surface-bound transferrin. We verified that the presence of 
saturating (1 mM) amounts of unbound Tf2 partially inhibits 
nanoparticle internalization, in line with the already discussed 
competitive inhibition (Fig S3). However, the inhibitory effect 
is not complete, presumably owing to the increased apparent 
affinity which occurs upon multimerization on the surface of 
nanostructured systems.36  
 
 
Figure 4: Internalization assay of gold nanoparticles 
conjugated with Tf2. Gold nanoparticles were coated with 
different percentage of PepN-Tf2 (0, 1 and 10% w/w) and 
incubated in human plasma 1 h at 37°C and then with Mia 
PaCa-2 cells for 1 h at 37°C in DMEM. Gold internalization was 
quantified by ICP-MS analysis on cells homogenate.  
Composition analysis of the protein corona adsorbed on the 
surface of coated nanoparticles 
Finally, we performed a proteomic analysis to fully 
characterize identity and amount of proteins adsorbed on the 
surface of nanoparticles upon incubation in a biological 
milieu. Peptide N is not optimized to confer antifouling 
properties; thus, it was expected that extensive protein 
adsorption would take place. Yet, the presence of a highly 
specific sequence such as Tf2 should promote differential 
adsorption of Tf. To this end, we prepared protein-coated 
nanoparticles by incubation with pure human plasma in 
physiological conditions (1 h at 37°C) as described above. 
After a washing and isolation step to remove loosely bound 
proteins, we analyzed adsorbed proteins by LC-MS/MS. We 
identified 68 proteins (see Supplementary material table 2) 
with 95% confidence level using Paragon algorithm. 
Transferrin was among the 15 most represented proteins on 
the nanoparticles surface (Table 2). Interestingly, 
comparative analysis evidenced higher amount of adsorbed 
Tf on the surface of AuNP-1 and AuNP-10 compared to AuNP-
0 (1.06 and 1.32 folds, respectively). Notably, there is an 
excellent agreement between the amount of adsorbed 
transferrin and internalization in cells, which is significative 
only in the case of AuNP-10. Note that in this case there is a 
large increase in internalization efficiency, if compared with 
the relatively small increase in adsorbed Tf (1.32 folds). It is 
tempting to explain this result with a better orientation of 
transferrin in the presence of Tf2 peptide, which promotes 
presentation of the active site of Tf towards the outer 
medium. This might increase the percentage of appropriately 
oriented Tf, which in turn could lead to significantly enhanced 
binding to TfR despite the formally similar concentration on 
the surface of the nanoparticle. It is worth noting that, along 
with transferrin, there are differences in some other 
representative proteins. Among the other represented 
proteins, which are actually common components of the 
“hard protein corona” formed on nanoparticles,37 content of 
apolipoprotein (entries 11, 14) and fibrinogen (entries 
12,13,15) decreases with increase of Tf2 peptide percentage, 
while immunoglobulin content does not show a clear trend, 
although a tendency to increase can be inferred from the 
available data. The overall decrease in aspecifically bound 
proteins could suggest a potential improvement of the 
biocompatibility of our system for potential therapeutic use, 
although the role of specific proteins should be further 
investigated. Finally, serum albumin content increases with 
Tf2 coverage, as expected in view of the reported interaction 
between HSA and Tf.38 Note that this interaction could 
actually be the main responsible for the observed increase in 
HSA content on targeted nanoparticles. It is tempting to 
assume that the observed increase of HSA content does not 
reflect a direct increased interaction, but rather an indirect 
effect of the increased Tf content.  
 
Table 2: Most abundant proteins identified by mass spectrometry on nanoparticle-protein corona complexes. Proteins are listed in 
decreasing order on the basis of their change on AuNP-10 compared to the control sample. 
Entry 







1 ALBU_HUMAN Serum albumin 1.64 1.38 
2 IGHG1_HUMAN Ig gamma-1 chain C region 1.28 1.10 
3 TRFE_HUMAN Serotransferrin 1.32 1.06 
4 FCN3_HUMAN Ficolin-3 1.42 1.12 
5 IGHM_HUMAN Ig mu chain C region 1.34 1.20 
6 IGKC_HUMAN Ig kappa chain C region  4.57 1.54 
7 IGHA1_HUMAN Ig alpha-1 chain C region 0.97 1.13 
8 LAC3_HUMAN Ig lambda-3 chain C regions 0.69 1.04 
9 ACTB_HUMAN Actin, cytoplasmic 1 0.77 0.95 
10 VTNC_HUMAN Vitronectin  0.82 1.21 
11 APOA1_HUMAN Apolipoprotein A-I  0.93 0.78 
12 FIBG_HUMAN Fibrinogen gamma chain  0.27 0.61 
13 FIBB_HUMAN Fibrinogen beta chain 0.31 0.67 
14 APOE_HUMAN Apolipoprotein E  0.33 0.31 
15 FIBA_HUMAN Fibrinogen alpha chain  0.24 0.45 
 
Conclusions 
In conclusion, we developed a new Tf-binding peptide 
rationally designed by in silico selection. This approach allows 
design of sequences that bind to target proteins without 
affecting their biological function, and does not require 
production and purification of massive amounts of the target 
protein, thus being easily exploitable for the development of 
sequences against rare or unstable proteins. The obtained 
peptide (Tf2) shows good binding efficiency towards its target 
with limited aspecific protein adsorption, and is efficiently 
internalized in cells by transferrin-mediated endocytosis. 
Furthermore, Tf2 can be conjugated to nanostructured 
compounds such as gold nanoparticles, and effectively 
promotes internalization in the presence of physiological (i.e. 
plasma) level of transferrin. Finally, we demonstrated, by 
means of proteomic analyses, that the targeting peptide Tf2 
modifies the protein corona composition on gold 
nanoparticles upon incubation in human plasma, thus 
opening new avenues in the development of nanostructures 
that acquire selectivity by spontaneous adsorption of specific 
serum/plasma proteins with controlled orientation. Further 
studies are in progress to improve the proposed algorithm to 
better filtering against aspecific binding, evaluate the 
potential of this sequence to the targeted delivery of 
therapeutics in vitro and in vivo, and develop new binding 
sequences against biologically relevant molecules. 
 
MATERIALS AND METHODS 
All chemicals were purchased from Sigma Aldrich unless 
otherwise specified, and were used as received. 
 
Identification of binding pocket 
Binding pockets on the transferrin were predicted using 
Fpocket24 and ranked according to their Voronoi volume (Fig 
1B). Only one pocket was identified as being wide enough to 
accommodate a hexapeptide. Moreover, the same binding 
pocket was present with minor changes in both the unbound 
and bound transferrin. 
 
Sequence design and QSAR analysis 
The in silico design procedure consists of a series of iterative 
steps, in which a regression model for the prediction of the 
physico-chemical requirement of binding is inferred from 
molecular dynamic simulations. As the iterative procedure 
goes on, the model is further optimized with information 
gathered from previous steps. In the first iteration, 
hexapeptides are randomly generated and molecular 
dynamic simulations (see next paragraph for details) are 
performed in order to associate a theoretical binding energy 
to each tested sequence. From the second iteration on, the 
information generated by MD simulations is used to build a 
regression model describing the physico-chemical 
requirements for binding. Peptide sequences are encoded 
into quantitative structure-activity relationship (QSAR) 
descriptors by using global features (net charge, isoelectric 
point) and topological features (auto- and cross-correlation of 
variables) as previously described27 (Table S1). In this study, 
the Support Vector Machine for regression (SMOReg), is used 
as implemented in the software suite WEKA39. Model 
performance was measured with a 10-fold cross-validation 
analysis, where the peptide dataset was divided into 10 parts 
- 9 parts for model learning (training) and the remaining part 
for validation (testing). The regression performance is 
evaluated by the Pearson correlation coefficient.  
A class of genetic algorithms called multi-objective 
evolutional algorithms (MOEA)40 is used in combination with 
the regression model to find a set of candidate sequences 
with a predicted high binding energy and at the same time 
minimize the number of charged/hydrophobic amino acids. In 
particular, hydrophobicity was measured with the Consensus 
Hydrophobicity Scale (CCS).26 This measure of hydrophobicity 
is based on a set of literature base scales, normalised and 
filtered by different methods. In order to avoid overfitting of 
candidate sequences, and exploring a wider space of the 
physico-chemical features, at each iteration 30% of the 
sequence library was designed by MOEA, while the remaining 
70% was randomly designed. In this work, 100 peptides were 
designed and virtually docked at each iteration, for a total of 
10 iterative steps. The top three peptides (Tf1, Tf2, Tf3) 
obtained at the last iteration by the MOEA were selected to 
be experimentally tested. Moreover, a scrambled version of 
Tf2 was generated in order to test for specificity. 
 
Molecular dynamic simulations 
Starting from a list of hexapeptide sequences, a library of all-
atom (AA) structures is generated by MODELLER41 using an 
extended hexapeptide as template. For each structure, an 
initial CG protein-peptide complex is assembled by placing 
the AA peptide in the target pocket and converting the 
resulting system to a CG MARTINI model with martinize.py 
script. The system is then minimized with 1000 step steepest 
descendent minimization, followed by an equilibration of 4ps. 
The temperature was maintained at 298K by coupling the 
system to a Nosè − Hoover thermostat. This allows resolving 
steric clashes due to the initial approximate positioning of 
hexapeptides into the binding pocket. The equilibrated 
complex is then backmapped to AA by MARTINI backmapping 
script using the CHARMM force field.42 The binding free 
energy is estimated at the last frame of the 4ps simulations 
using the molecular mechanics Poisson-Boltzmann surface 
area (MM-PBSA) method as implemented in g_mmpbsa25. 
This procedure is repeated 10 times for each peptide, in order 
to verify its reproducibility and increase statistics. 
 
Analysis of docked poses 
Selected peptides (Tf1, Tf2, Tf2-scrambled, Tf3) where 
subjected to 1ns molecular dynamics simulations within the 
Tf pocket. Molecular dynamics simulations have been 
performed as described hereafter. The system was solvated 
with TIP3P water molecules ensuring a minimum distance to 
the box edge of 1 nm. A steepest-descent minimization was 
applied to relax the solvent molecules. The system was 
thermalized up to 300 K using a V-rescale thermostat (𝜏𝜏𝑡𝑡 =
0.1) in the canonical ensemble. One nanosecond simulation 
was then performed in the normal temperature and pressure 
(NPT: p=1 bar, T=300 K) statistical ensemble coupling the 
system with a Parrinello-Rahman barostat (𝜏𝜏𝑝𝑝 = 2). All bonds 
were constrained with LINCS43, allowing to use a time step set 
of 2 fs. Periodic boundary conditions were applied to the 
systems in all directions. PME method44 was used to evaluate 
long-range electrostatic interactions (pme order=4, fourier 
spacing=0.12), and a cutoff of 10 Å was used to account for 
the van der Waals interactions. Coordinates of the systems 
were collected every 2 ps. Simulations were performed using 
GROMACS 5.045 using the CHARMM force field. Hierarchical 
cluster analysis was then applied to the equilibrium 
trajectories using the silhouette method for determining the 
best number of clusters. The centroid of the most populated 
cluster was used as representative docked pose. 
 
Peptide synthesis and purification  
All peptides were prepared by solid-phase synthesis using 
Fmoc chemistry on an automatic Liberty Blue Peptide 
Synthesizer with an integrated microwave system (CEM, 
North Carolina, USA). HPLC analysis and purification were 
performed on a Dionex Ultimate 3000 PLC system with 
autosampler. Crude peptides were purified by RP-HPLC on a 
Jupiter 4 µm Proteo 90 Å column (250×10 mm; Phenomenex) 
using these solvents: water:TFA 100:0.01 v/v (eluent 
A)/acetonitrile:water:TFA 95:5:0.01 v/v (eluent B), flux 5 
ml/min. The identity of purified product was confirmed by 
electrospray mass spectroscopy, using an API3200QTRAP 
Hybrid Triple Quadrupole/Linear Ion Trap (ABSciex, Foster 
City, California, USA). 
 
Conjugation with fluorophores 
All peptides were conjugated with the Atto633-maleimide 
(ATTO-TEC GmbH, Germany) fluorophore by means of 
maleimide-thiol coupling chemistry. The reaction was 
conducted in Hepes buffer (20 mM, pH= 7.2) under stirring at 
25°C at least for 2 hours. Analytical evaluation of labeling 
reaction and purity of the labeled peptide was performed on 
a Jupiter Proteo 90 Å column (4µm, 250×10 mm; 
Phenomenex) using these solvents: water:TFA 100:0.01 v/v 
(eluent A)/acetonitrile:water:TFA 95:5:0.01 v/v (eluent B), 
flux 1 ml/min. The identity of purified product was confirmed 
by electrospray mass spectroscopy. 
 
QCM-D measurements 
Quartz crystal microbalance measurements were carried out 
with a dissipative QCM (Q-Sense, Gothenburg, Sweden) using 
AT-cut 5 MHz quartz crystals coated with a 3–100 nm thick 
layer of gold (Biolin Scientific, Stockholm, Sweden) at 25°C. 
Before use, they were cleaned with ethanol and dried under 
nitrogen flow. Experiments were carried out in stopped-flow 
mode using a syringe pump operating at a flow rate of 100 
μl/min and PBS as carrier buffer. Data were simultaneously 
acquired at the fundamental frequency F of 5 MHz (N = 1) and 
several overtone frequencies (15, 25, 35, 45, and 55 MHz, i.e. 
N = 3, 5, 7, 9 and 11). The curves shown in Fig. S1 are those 
obtained with the ninth harmonics (45 MHz). We used each 
peptide at a concentration of 10 μM and increasing 




Human adenocarcinoma pancreatic cells (Mia PaCa-2) were 
purchased from the American Type Culture Collection (ATCC) 
and were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) from Invitrogen (Carlsbad, CA). Growth medium was 
supplemented with 10% fetal bovine serum (FBS), 4 mM L-
Glutamine, 1 mM Sodium Pyruvate, 100 U/ml penicillin and 
100 mg/ml streptomycin (Invitrogen). Cells were maintained 
at 37°C in a humidified 5% CO2 atmosphere. 
 
Confocal microscopy 
Cells were seeded 24 h before the experiments into glass-
bottom petri dish (WillCo-dish GWSt-3522) to reach 80-90% 
of confluence. Incubation of peptides was performed for 30 
minutes at 37°C or 4°C, 5% CO2 in DMEM with 10% FBS at a 
final concentration of 1 μM in a total volume of 200 μl. After 
incubation, cells were washed twice with PBS, fresh medium 
was added and the samples were analyzed by confocal 
microscopy. We tested all type of endocytosis with the same 
incubation condition but adding different fluorescent 
markers together with the peptides. For clathrin-mediated 
endocytosis we used 5 μM of hTransferrin-Alexa488 and we 
added the right amount of unlabeled hTF to a total 
concentration of 35 µM, comparable with the one in the 
human plasma. In the same experimental conditions, 
colocalization of the peptide with Lysotracker Green (final 
concentration: 70 nM) confirmed this internalization pathway 
and final compartmentalization in lysosomes. For 
macropinocytosis we used 1 mg/ml of Dextrans (70kDa) 
labeled with FITC and for caveolin-mediated endocytosis we 
used Mia PaCa-2 cells transfected with caveolin-GFP. In both 
cases the amount of Tf was due only to the FBS added to the 
medium (approximately 3 µM). Cells were imaged using a 
Leica TCS SP5 SMD inverted confocal microscope (Leica 
Microsystems AG) interfaced with Ar and DPSS laser for 
excitation at 488 nm and 561 nm respectively. Cells were 
mounted in a thermostated chamber at 37°C (Leica 
Microsystems) and viewed with a 40x 1.5 NA oil immersion 
objective (Leica Microsystems). The pinhole aperture was set 
to 1.0 Airy. All images were analyzed using ImageJ software 
1.48v and colocalization was evaluated using JACoP plugin. 
The final value of Pearson’s Coefficient is an average obtained 
from the analysis of 10 images taken with the same 
magnification for each experiment. 
 
Synthesis of gold nanoparticles and peptide conjugation 
Gold seeds were prepared46 by refluxing for 30 min 100 mL of 
aqueous solution of HAuCl4 (1 mM) with sodium acrylate (24 
mM). The reaction produced a deep-red colloid characteristic 
of 14 nm spheres. For the second step all the seed solution 
was mixed to 15 mL of 25 mM HAuCl4 solution and diluted in 
845 mL of MilliQ water. The mixture was brought to pH = 7 
and 40 mL of 0.5 M acrylic acid solution was added. After 3 
days at 22 °C under continuous stirring; the reaction produced 
a wine-red solution of 30 ± 1.7 nm gold nanoparticles at a 0.5 
nM (2.92 x 1011 NP ml-1) concentration. For peptide 
conjugation, 1 ml of the above colloid was centrifuged for 5 
minutes at 13,000 rpm and resuspended in 900 μl of DMF. 
Starting from solution of 1 mM for both peptides, three 
different peptide solutions were made (only peptide N, 
peptide N + peptide N-Tf2 99:1 and peptide N + peptide N-Tf2 
90:10) to a final volume of 100 μl, which was added to 
nanoparticles solution and stirred for 90 minutes at 4°C. After 
incubation, conjugated nanoparticles were washed thrice 
with TEA buffer and resuspended in 100 μl of the same buffer. 
 
Plasma incubation and isolation of nanoparticles with 
protein corona 
Conjugated nanoparticle suspensions (100 μl) were incubated 
with 250 μl of human plasma, in a total volume of 350 μl and 
were stirred for 1 h at 37 °C. After incubation samples were 
centrifuged at 4°C to pellet the nanoparticle-protein complex. 
The pellets were washed thrice with PBS-EDTA buffer (PBS 1X, 
EDTA 1 mM and pH = 7.5) and resuspended in PBS-EDTA 
buffer to a final volume of 20 μl. Each sample was prepared 
in double for the internalization assay by ICP-MS and for 
proteomics analysis by LC-MS/MS. 
 
Gold nanoparticles internalization in living cells 
In order to verify the targeting capabilities of the conjugated 
nanoparticles produced as above described, gold was 
quantified by means of ICP-MS after incubation in living cells. 
Cells were seeded 24 h before experiments in a 12-well plate 
to reach 80-90% of confluence. Nanoparticles were 
maintained in human plasma from healthy donors for 1 h at 
37°C under continuous stirring and then diluted with serum-
free DMEM to obtain a final concentration of plasma of 10%. 
The solution was administered to Mia-PaCa-2 and incubated 
for 1 h. After this time cells were washed once with PBS and 
once with a I2/KI solution (ratio 1:6 with I2 at a final 
concentration of 0.34 mM) for 5 minutes to eliminate 
nanoparticles attached on cell surface.35 Then we discarded 
the supernatant, we washed once with PBS and we digested 
the cells with 0.2 ml of aqua regia. Samples were analyzed by 
ICP-MS (7700 series ICP-MS, Agilent Technologies) to quantify 
gold. Untreated cells were processed, digested, and used to 
determine blank signal. This contribution was subtracted to 
the signal obtained for treated cells. Data in Fig. 4 represent 
the average of three independent experiments and error bars 
state the standard error. A one-way ANOVA and t-test were 
used to assess differences in the data with p≤0.05, considered 
as statistically significant. 
 
Nano LC-MS/MS SWATHTM proteomics analysis  
Particles with their corona were suspended in 100 μl of 25 
mM Ammonium Bicarbonate/ 10% Acetonitrile (ACN, Romil, 
UK) and vortexed. 50 μl of suspension were diluted again to 
100 μl, reduced 30 min with 5 mM Dithiothreitol @ 80°C, 
alkylated adding 10 mM of Iodoacetamide at 37°C for 20 min 
and digested overnight with 0.6 mg/ml of trypsin (Roche, 
Germany) at 37°C. Peptide solutions were acidified and 
centrifuged for 10 min at 10°C and 13000 rpm in order to 
discard nanoparticles; supernatant was loaded on a C18 
cartridge and filtered on a 0.22 μm filter. Eluate was 
evaporated in a SpeedVac (Savant) and diluted to 50 µL of 2% 
ACN/0.1% Formic Acid (FA); 5 µl of each sample were injected 
for library and 5 µl in duplicate for SWATH analysis. 
Chromatographic separation of eluted peptides was 
performed using a nano-HPLC system (Eksigent, ABSciex, 
USA). A first load step pre-concentrated the sample in a pre-
column cartridge (PepMap-100 C18 5 µm 100 A, 0.1 x 250 
mm, Thermo Scientific, USA) and then peptides were 
separated in a C18 PepMap-100 column (3 µm, 75 µm x 150 
mm, Thermo Scientific, USA) at a flow rate of 300 nl min-1. 
Runs were performed with eluent A (Ultrapure water, 0.1% 
FA) in a 70 min linear gradient from 5 to 40% of eluent B 
(ACN/0.1% FA) followed by 10 min of a purge step and 20 min 
re-equilibration step. Peptides eluted from chromatography 
were directly analysed using a TripleTOFTM 5600 mass 
spectrometer (ABSciex, USA) equipped with a DuoSprayTM ion 
source (ABSciex, USA). Data for protein library were acquired 
in IDA (information dependent acquisition) mode, survey 
scans were acquired in 250 ms and 25 product ion scans. 
MS/MS data were processed with ProteinPilotTM Software 
(ABSciex, USA) using SwissProt database for Homo sapiens 
(updated to May 2016). The false discovery rate (FDR) analysis 
was set to a confidence level of 95%. The label free 
comparative analysis of samples was performed on data 
acquired using SWATHTM method for shotgun data 
independent MRM quantification, loaded into PeakViewTM 
Software (ABSciex, USA) with MS/MS(ALL) with SWATH™ 
Acquisition MicroApp 2.0 and MarkerViewTM (ABSciex, USA). 
Retention time alignment was obtained using selected 
peptides (top confidence and top level transitions) from top 
score protein. Processing settings were: 7 peptides per 
protein, 7 transitions per peptide, 74% peptide confidence 
(according to Paragon algorithm result) and 5% FDR; XIC 
options: extraction window 10 min, width 50 ppm and 0.1 Da. 
Normalization was done using a global normalization of 
profiles (total protein content) on chromatographic area, 
then protein intensity from serum “blank” sample was 
subtracted to respective sample protein intensity. Blank 
corrected data were compared to evidence fold change 
across samples. 
 
SUPPORTING INFORMATION AVAILABLE 
 
List of descriptors for in silico peptide analysis, QMC 
measurements, additional microscopy images and tables of 
proteomics analysis.  
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